Innovative Medicines Initiative (IMI2): CALLS 3 and 4

The following two IMI2 calls were announced on 17th December 2014:


Call 4:

Call ID: H2020-JTI-IMI2-2015-04-two-stage

Action type: Coordination and Support Action

Deadline: 11/2/2015 (stage1), 14/4/2014 (stage 2)


Topic 1: Enabling Platform on Medicines Adaptive Pathways to Patients

The consortium of applicants is expected to have knowledge of the following:

  • Knowledge and expertise in medicinal products’ life cycle;
  • Sound understanding of the R&D pathways and their challenges;
  • Ability to develop outreach and communication strategies on the role and challenges of MAPPs to the stakeholders and public at large;
  • Proven expertise for managing and coordinating major projects of this complexity and scale;


More Information:


Call 3:

Call ID: H2020-JTI-IMI2-2015-03-two-stage

Action Type: Research and Innovation Action

Deadline: 24/3/2015 (stage1), 22/9/2014 (stage 2)


Topic 1: Remote assessment of disease and relapse – CNS

Applicant consortium will be multidisciplinary:

  • device and sensor companies to bring the latest remote assessment technologies that could be further developed or modified for use as intended in CNS diseases;
  • Academic, clinical and disease area experts will help to design the clinical study (end-points, inclusion criteria etc.) and interpret results for clinical significance;
  • IT/ analytics partners will help develop data management architecture, state-of-the-art algorithms to derive biosignatures of symptoms and relapse from collected streaming data;
  • Regulatory and health-care systems experts will help define regulatory and clinical-care pathways respectively for the remote assessment solutions.


Topic 2: Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification

Applicant consortium will be multidisciplinary:

  • basic, translational, clinical research;
  • regulatory aspects;
  • economic or public health modelling;
  • project management.
  • complementary expertise in:
  • biomarker discovery and clinical assay implementation across the range of relevant technologies, in human pancreatic beta cell, hepatic, muscle, and adipose biology,
  • conducting intensive clinical phenotyping of prediabetes and type 2 diabetes patients, and
  • prospective and retrospective assembly and assessment of large longitudinal cohorts and biobanks from subjects with prediabetes and type 2 diabetes


Topic 3: Linking clinical neuropsychiatry and quantitative neurobiology

Applicant consortium will be multidisciplinary:

  • statistics and study design;
  • clinical study support;
  • IT – Data communication and data basing;
  • quantitative clinical technologies and biomarkers;
  • pre-clinical technologies that are aligned with those identified for use clinically;
  • regulatory expertise
  • translational medicine expertise;
  • project management.


Topic 4: The consistency approach to quality control in vaccine manufacture

The Applicant Consortium is expected to provide both pre-clinical (safety, CMC, assay development) and clinical expertise and ability for interdisciplinary and inter-sectorial work and to cover the following critical fields:

  1. Physicochemical techniques for conformational fingerprinting of antigens
  2. Proteolytic susceptibility of antigens to mimic APC action
  3. Immunochemical assay development
  4. Manufacturing processes and production consistency
  5. Antigen-adjuvant interactions
  6. In vitro cell models of Immune responses
  7. Genomic and proteomic profiling
  8. Regulatory expertise
  9. Understanding of GLP, QA
  10. Animal models and laboratory animal science


Topic 5: Pertussis vaccination research

  • Expertise in in vitro , preclinical and clinical B. pertussis research or pertussis vaccination
  • Expertise in the development of bioassays or immunoassays suitable to assess pertussis infection and functional and memory immune responses to pertussis vaccination.
  • Expertise in the identification of human biomarkers of infectious disease progression, immunological memory and/or vaccine efficacy
  • Expertise in molecular epidemiology and use on in silico tools to investigate pathogen biodiversity and epidemiology of infectious disease
  • Expertise and infrastructure needed to set up preclinical disease models, including in non -human primates
  • Expertise and infrastructure to perform prospective clinical studies with licensed pertussis vaccines, as well as access to relevant vaccination cohorts
  • Institutional expertise /infrastructure to develop and perform control bacterial/respiratory pathogen challenge studies in human volunteers
  • Expertise or access to epidemiological data on pertussis disease and effectiveness of pertussis vaccination
  • Banking and Documenting clinical isolates of B. pertussis or biological samples from infected or vaccinated individuals


Topic 6: Knowledge repository to enable patient focused medicine development

  • Experience with Patient Advocacy
  • Regulatory Expertise
  • Health Services Research
  • Clinical Informatics
  • Infrastructure and Software
  • Advanced Knowledge Management
  • Point of Care Know-how and Integration
  • Community Education and Learning
  • Education Systems
  • Learning and training Management
  • Analysis and complex clinical workflow experience
  • Drug Development Life Cycle
  • Innovation
  • Requirements Engineering
  • Product Development


More Information: your social media marketing partner